Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime

Hanke, Tomáš; Neumann, Veronica; Blanchard, Tom; Sweeney, Paul; Hill, Adrian V. S.; Smith, Geoffrey L.; McMichael, Andrew J.

doi:10.1016/s0264-410x(98)00238-2

Cited by 102 publications

(73 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been shown that to induce a stronger CTL response, immunizations may be given i.m. with DNA encoding CTL epitopes, followed by a gene gun booster of modified vaccinia Ankara, and that specific HIV-1 immune responses are increased as a result of the boosting strategy (13).…”

Section: Figurementioning

confidence: 99%

“…Prime-booster immunization with DNA vaccine encoding the gp of herpes simplex virus (gB) 3 expressed and attenuated recombinant vaccinia virus vector (rvacgB) induced mucosal and systemic responses (12). DNA constructs encoding multi-CTL epitopes from human, macaques, and mice have also been administrated i.m., enhancing HIV-specific CTL epitopes (13). Abs have been administrated to prevent HIV transmission, such as mAbs 2F5 and 2G12, which protected macaques against SHIV vaginal challenge (14).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Intranasal HIV-1-gp160-DNA/gp41 Peptide Prime-Boost Immunization Regimen in Mice Results in Long-Term HIV-1 Neutralizing Humoral Mucosal and Systemic Immunity

Devito

Zuber

Schröder³

et al. 2004

The Journal of Immunology

View full text Add to dashboard Cite

An intranasal DNA vaccine prime followed by a gp41 peptide booster immunization was compared with gp41 peptide and control immunizations. Serum HIV-1-specific IgG and IgA as well as IgA in feces and vaginal and lung secretions were detected after immunizations. Long-term humoral immunity was studied for up to 12 mo after the booster immunization by testing the presence of HIV-1 gp41- and CCR5-specific Abs and IgG/IgA-secreting B lymphocytes in spleen and regional lymph nodes in immunized mice. A long-term IgA-specific response in the intestines, vagina, and lungs was obtained in addition to a systemic immune response. Mice immunized only with gp41 peptides and L3 adjuvant developed a long-term gp41-specific serum IgG response systemically, although over a shorter period (1–9 mo), and long-term mucosal gp41-specific IgA immunity. HIV-1-neutralizing serum Abs were induced that were still present 12 mo after booster immunization. HIV-1 SF2-neutralizing fecal and lung IgA was detectable only in the DNA-primed mouse groups. Intranasal DNA prime followed by one peptide/L3 adjuvant booster immunization, but not a peptide prime followed by a DNA booster, was able to induce B cell memory and HIV-1-neutralizing Abs for at least half of a mouse’s life span.

show abstract

Section: Figurementioning

confidence: 99%

mentioning

confidence: 99%

Intranasal HIV-1-gp160-DNA/gp41 Peptide Prime-Boost Immunization Regimen in Mice Results in Long-Term HIV-1 Neutralizing Humoral Mucosal and Systemic Immunity

Devito

Zuber

Schröder³

et al. 2004

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…The mel3 sequence encodes the following CTL epitopes in sequence: tyrosinase [1][2][3][4][5][6][7][8][9] The DNA vector pSG2, used throughout the study, was derived from pRc/CMV (Invitrogen, Paisley, U.K.).…”

Section: The Mel3 Polyepitope Constructmentioning

confidence: 99%

Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols

Palmowski

Choi

Hermans

et al. 2002

The Journal of Immunology

141

107

View full text Add to dashboard Cite

Recombinant vaccines encoding strings of virus- or tumor-derived peptides and/or proteins are currently being designed for use against both cancer and infectious diseases. These vaccines aim to induce cytotoxic immune responses against several Ags simultaneously. We developed a novel tetramer-based technique, based on chimeric HLA A2/H-2Kb H chains, to directly monitor the CTL response to such vaccines in HLA-A2 transgenic mice. We found that priming and boosting with the same polyepitope construct induced immune responses that were dominated by CTL of a single specificity. When a mixture of viruses encoding single proteins was used to boost the polyepitope primed response, CTL of multiple specificities were simultaneously expanded to highly effective levels in vivo. In addition, we show that a preexisting response to one of the epitopes encoded within a polyepitope construct significantly impaired the ability of the vaccine to expand CTL of other specificities. Our findings define a novel vaccination strategy optimized for the induction of an effective polyvalent cytotoxic response.

show abstract

“…In an effort to address these issues, some investigators are in the process of developing multivalent or multimeric HIV-1 vaccine strategies. Approaches include the use of multiple DNA or vaccinia virus (VV) vectored gp120 immunogens (192,193), as well as the development of multiepitope "universal" CTL immunogens capable of class-I restricted presentation by 90% of more of the human population (194)(195)(196). The International AIDS Vaccine Initiative (IAVI) is currently sponsoring studies which are ultimately intended to assess the safety and immunogenicity of this approach in humans.…”

Section: Multivalent Vaccinesmentioning

confidence: 99%

Pathogenesis and treatment of HIV-1 infection: recent developments (Y2K update)

Tel:716-275-3216¹

2000

Front Biosci

View full text Add to dashboard Cite

Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime

Cited by 102 publications

References 44 publications

Intranasal HIV-1-gp160-DNA/gp41 Peptide Prime-Boost Immunization Regimen in Mice Results in Long-Term HIV-1 Neutralizing Humoral Mucosal and Systemic Immunity

Intranasal HIV-1-gp160-DNA/gp41 Peptide Prime-Boost Immunization Regimen in Mice Results in Long-Term HIV-1 Neutralizing Humoral Mucosal and Systemic Immunity

Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols

Pathogenesis and treatment of HIV-1 infection: recent developments (Y2K update)

Contact Info

Product

Resources

About